Exicure, Inc. Class Action Lawsuit - XCUR
- Company Name
- Exicure, Inc.
- Stock Symbol
- Class Period
- March 11, 2021 to November 15, 2021
- Motion Deadline
- February 11, 2022
- Northern District of Illinois
The Exicure class action lawsuit seeks to represent purchasers of Exicure, Inc. (NASDAQ: XCUR) securities between March 11, 2021 and November 15, 2021, inclusive (the “Class Period”) and charges Exicure along with certain of its top executives with violations of the Securities Exchange Act of 1934. The Exicure class action lawsuit was commenced on December 13, 2021 in the Northern District of Illinois and is captioned Colwell v. Exicure, Inc., No. 21-cv-06637.
If you wish to serve as lead plaintiff of the Exicure class action lawsuit, please provide your information by clicking here. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at email@example.com. Lead plaintiff motions for the Exicure class action lawsuit must be filed with the court no later than February 11, 2022.
CASE ALLEGATIONS: Exicure is a clinical stage biotechnology company that develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and other genetic disorders based on its proprietary spherical nucleic acid technology.
The Exicure class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) there had been certain improprieties in Exicure’s preclinical program for the treatment of Friedreich’s ataxia; (ii) as a result, there was a material risk that data from the preclinical program would not support continued clinical development; and (iii) consequently, defendants’ positive statements about Exicure’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On November 15, 2021, Exicure filed a Form 12b-25 with the United States Securities and Exchange Commission stating that it could not timely file its quarterly report for the period ended September 30, 2021. Exicure explained that Exicure was investigating “a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to the Company’s XCUR-FXN preclinical program for the treatment of Friedreich’s ataxia.” On this news, Exicure’s stock price fell approximately 28%, damaging investors.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Exicure securities during the Class Period to seek appointment as lead plaintiff in the Exicure class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Exicure class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Exicure class action lawsuit. An investor’s ability to share in any potential future recovery of the Exicure class action lawsuit is not dependent upon serving as lead plaintiff.
ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 lawyers in 9 offices nationwide, Robbins Geller Rudman & Dowd LLP is the largest U.S. law firm representing investors in securities class actions. Robbins Geller attorneys have obtained many of the largest shareholder recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for recovering $1.6 billion for investors that year, more than double the amount recovered by any other securities plaintiffs’ firm.